TOI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TOI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). The Oncology Institute's Cash per Share for the quarter that ended in Dec. 2024 was $0.66.
The historical data trend for The Oncology Institute's Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Cash per Share | Get a 7-Day Free Trial | 0.09 | 1.56 | 1.01 | 1.12 | 0.66 |
The Oncology Institute Quarterly Data | ||||||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Cash per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.12 | 0.89 | 0.61 | 0.63 | 0.66 |
This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.
The Oncology Institute's Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 49.669 | / | 75.7 | |
= | 0.66 |
The Oncology Institute's Cash per Share for the quarter that ended in Dec. 2024 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 49.669 | / | 75.7 | |
= | 0.66 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Oncology Institute (NAS:TOI) Cash per Share Explanation
Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.
Thank you for viewing the detailed overview of The Oncology Institute's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeremy Castle | officer: Chief Operating Officer | 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mark L Pacala | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Karen Marie Johnson | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Brad Hively | director, officer: Chief Executive Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Daniel Virnich | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Yale Podnos | officer: Chief Medical Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richard A Barasch | director, officer: Executive Chairman | C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573 |
Havencrest Healthcare Partners, L.p. | 10 percent owner | 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039 |
Mihir Shah | officer: Chief Financial Officer, other: Principal Financial Officer | C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801 |
Matthew P Miller | officer: Chief Operating Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Diona Simoneit | officer: Chief Accounting Officer, other: Principal Accounting Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Mohit Kaushal | director | 44 SOUTH BROADWAY, WHITE PLAINS NY 10601 |
Gabriel Ling | director | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Richy Agajanian | 10 percent owner | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
Scott Dalgleish | officer: Chief Financial Officer | C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703 |
From GuruFocus
By GuruFocus Research • 03-28-2024
By GuruFocus News • 11-14-2024
By Marketwired • 05-22-2024
By Marketwired • 11-13-2024
By Marketwired • 03-04-2025
By Marketwired • 09-30-2024
By GuruFocus News • 03-26-2025
By GuruFocus Research • 05-15-2024
By GuruFocus News • 03-26-2025
By Marketwired • 03-24-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.